Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Aclaris Therapeutics, Inc. (ACRS)
|
Add to portfolio |
|
|
|
| Price: |
$14.59
| | Metrics |
| OS: |
70.8
|
M
| |
-59
|
% ROE
|
| Market cap: |
$1.03
|
B
| |
-59
|
% ROIC
|
|
Net cash:
|
$211
|
M
| |
$2.98
|
per share
|
|
EV:
|
$822
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($104)
|
M
| |
|
|
|
EBIT
|
($105)
|
M
| |
|
|
| EPS |
($1.56)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 29.8 | 6.8 | 6.5 | 4.2 | 6.2 | 1.7 | 0.0 | 0.0 |
| Revenue growth | 340.1% | 4.3% | 53.3% | -31.3% | 265.5% | | | |
| Cost of goods sold | 4.0 | 4.7 | 5.1 | 4.1 | 4.3 | 1.2 | 0.0 | 0.0 |
| Gross profit | 25.7 | 2.0 | 1.3 | 0.2 | 1.8 | 0.5 | 0.0 | 0.0 |
| Gross margin | 86.5% | 30.3% | 20.8% | 4.1% | 29.6% | 28.3% | | |
| Sales and marketing | | | | | | 0.1 | 3.3 | |
| Research and development | 77.8 | 43.8 | 29.3 | 64.2 | 60.8 | 35.8 | 33.5 | 15.3 |
| General and administrative | 25.1 | 23.6 | 20.5 | 27.8 | 25.8 | 18.9 | 11.8 | 5.3 |
| EBITA | -85.1 | -65.3 | -48.4 | -92.5 | -84.7 | -54.3 | -48.6 | -20.7 |
| EBITA margin | -286.0% | -966.0% | -747.4% | -2187.8% | -1377.1% | -3228.2% | | |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | | |
| EBIT | -85.2 | -65.4 | -48.5 | -92.6 | -84.8 | -54.4 | -48.6 | -20.7 |
| EBIT margin | -286.2% | -967.1% | -748.5% | -2189.6% | -1378.3% | -3230.0% | | |
| Pre-tax income | -86.9 | -90.9 | -51.3 | -113.5 | -82.1 | -70.4 | -48.1 | -20.6 |
| Income taxes | 0.0 | 0.0 | -0.2 | 47.8 | 50.6 | -1.8 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.4% | | | 2.6% | 0.0% | 0.0% |
| Earnings from continuing ops | -86.9 | -90.9 | -51.2 | -113.5 | -82.1 | -52.3 | -48.1 | -23.1 |
| Earnings from discontinued ops | | | | | -50.6 | -18.1 | | |
| Net income | -86.9 | -90.9 | -51.0 | -161.4 | -132.7 | -68.5 | -48.1 | -23.1 |
| Net margin | -292.1% | -1344.0% | -787.0% | -3817.2% | -2158.0% | -4071.5% | | |
| |
| Diluted EPS | ($1.33) | ($1.60) | ($1.20) | ($2.75) | ($2.49) | ($1.86) | ($2.25) | ($3.79) |
| Shares outstanding (diluted) | 65.2 | 56.7 | 42.5 | 41.3 | 32.9 | 28.1 | 21.4 | 6.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|